August 19, 2022 7:44am

Review the highs of the 2021 advancing into 2022 and the continuing share pricing downfalls; will coming higher interest rates choke off even more of the upside in the market and reflexively cell and gene therapy sector

Pre-open indications: 3 Negative Indication, 3 Sells into Strength and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

I DEVOTE a HUGE amount of time to “reckoning” the geography of my coverage group - it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.80% or (-271 points), S&P futures are DOWN -0.97% (-41 points) and NASDAQ futures are DOWN -1.09% (-148 points) early in the pre-open – so far,


Stock futures were lower and falling on Friday,

European markets were lower,

Asia-Pacific markets were mostly flat.



The stock market rally traded in a narrow range for most of Thursday's session.

The Dow closed UP +18.72 points (+0.06%); the S&P closed UP +9.70 points (+0.23%) while the Nasdaq closed UP +27.22 points (+0.21%)


RegMed Investors’ (RMi) closing bell: “slipping, sliding and with some upside gliding before the close.  The "Slipping and Sliding" song seems to be referring to messing up (slipping) and messing up' on purpose (sliding) – a response to inflation and possibly the costs of developing therapies and their pricing after an approval.”


Ebb and flow –

Q3/22 – August – 7 positive and 7 negative closes

July - 1 holiday, 10 negative and 10 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Sell Into Strength:

BioLife Solutions (BLFS) closed up +$1.02 to $23.75 after Wednesday’s -$2.62, Tuesday’s -$0.66 and Monday’s +$1.42 with a positive +$1.18 or +4.97% pre-open indication

Ultragenyx (RARE) closed up +$1.42 to $48.67 after Wednesday’s -$2.06, Tuesday’s -$1.89 and Monday’s -$0.37) with a positive +$1.17 or +2.40% pre-open indication,

uniQure NV (QURE) closed up +$0.53 to $19.22 after Wednesday’s -$0.80 with a positive +0.28 or +1.46% pre-open indication,


Negative Indications:

CRISPR Therapeutics (CRSP) closed up +$0.41 to $72.15 after Wednesday’s -$4.11, Tuesday’s -$4.29 and Monday’s +$1.48 with a negative -$2.00 or -2.77% pre-open indication.

Editas Medicine (EDIT) closed down -$0.38 to $15.04 after Wednesday’s -$1.02, Tuesday’s -$1.12 and Monday’s -$0.31 with a negative -$0.14 or -0.88% pre-open indication.

Voyager Therapeutics (VYGR) closed up +$0.28 to $6.09 with a negative -$0.30 or -4.93% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed down -$0.15 with 790 shares traded after Wednesday’s +$0.15 with 1,035 shares traded, Tuesday’s flat (with 1,824 shares traded), Monday and last Friday <3 mo. Average = 962 shares>

·         Its BOD approved on 7/28 amending and restating their Certificate of Incorporation to affect a reverse split of the issued and outstanding common stock at a ratio of not less than 1-for-1.25 and not greater than 1-for-5. What about all those PPM (private placements) as an offering follows?

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

  • Are we in favor of Beijing funding and continue to control BSTG in our own country? Another question, makes one wonder, Newbridge Securities?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         New CFO, number #7 for the chute?

  • Be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities?


The BOTTOM LINE: I try to keep it simple … and short!

As I have written, I devote a lot of time to the direction of the sector to “reckon” the geography of my coverage group.”

Sorry since recent lower back injury; I now (temporarily) treading slowly with a “walking stick” having over done it in yard work which as I have been told – NO more.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.